

Payment Policy | **TEMPORARY** Coronavirus (COVID-19) Diagnostic Testing



EFFECTIVE DATE: 03|06|2020

POLICY LAST UPDATED: 04|03|2020

OVERVIEW

This policy addresses testing for Coronavirus (COVID-19).

This policy applies to Blue Cross & Blue Shield of Rhode Island (BCBSRI) participating providers, including, but not limited to the Rhode Department of Health Laboratory as well as non-participating or Out-of-Network providers with BCBSRI. However, please note that BCBSRI participating providers should continue to refer to an in-network laboratory when possible.

BCBSRI reserves the right to implement and revoke this policy and/or make a change to the waiver of member cost share without the contractual sixty-day (60) notification for a change in policy that is normally required under BCBSRI contracts with its providers. This would apply both for the effective date, due to the urgent and emergent nature of a pandemic, as well as for the withdrawal of the policy.

Notice of the implementation and withdrawal of this policy will only be communicated to BCBSRI providers via a notice on BCBSRI's provider website/portal under Alerts and Updates.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare and Commercials Products

Diagnostic laboratory testing related to COVID-19 is covered by Blue Cross & Blue Shield of Rhode Island (BCBSRI) under the members laboratory benefit for those members that meet the United States Centers for Disease Control and Prevention (CDC) guidelines/indications for testing and/or those guidelines/indications set forth/established by the Rhode Island Department of Health.

In adherence with the Rhode Island Office of the Health Insurance Commissioner & Medicaid Program Instructions During the COVID-19 State of Emergency issued on March 13, 2020, BCBSRI will **TEMPORARILY** waive cost-share (e.g. co-pays and/or deductibles) for diagnostic laboratory testing and the collection of specimens related to COVID-19 (see Coding Section for applicable HCPCS codes) when the following criteria are met:

- Testing is consistent with and members meet the guidelines set forth by the United States Centers for Disease Control and Prevention (CDC) and/or the Rhode Island Department of Health, and
- Testing must be processed by an FDA-approved lab.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable laboratory services benefits/coverage.

BCBSRI Cost Share Waiver

BCBSRI will waive all member cost share for BCBSRI subscribers (waiver of the cost share does not/may not apply to BlueCard HOST members/those members of other Blue Cross Blue Shield Plans nationally) for

laboratory testing and specimen collection related to COVID-19 as outlined in this policy, during the time period this policy is in effect. Providers should NOT collect cost share from a member in accordance with this policy.

Please note that BCBSRI self-insured/administrative services only accounts may elect to opt out of this policy and continue to apply subscriber cost share those subscribers covered under their benefit plan. BCBSRI will take all reasonable steps to inform and maintain a listing of those self-insured accounts that opt out of this policy. A listing of such self-insured accounts will be maintained on BCBSRI.com.

BACKGROUND

Effective for dates of service on or after February 4, 2020, Centers for Medicare and Medicaid Services (CMS) has developed Healthcare Common Procedure Coding System (HCPCS) billing codes, U0001 and U0002 to bill for tests and track new cases of the virus. Code U0001 may be used for CDC testing laboratories. Code U0002 may be used for tests established by laboratories that develop their own validated COVID-19 diagnostics when submitting claims to Medicare or health insurers.

Effective for dates of service on or after March 13, 2020, the American Medical Association (AMA) created a new CPT (Current Procedural Terminology) code, 87635, that will streamline coronavirus testing offered by hospitals, health systems and laboratories in the United States. It is intended as industry standard for reporting of novel coronavirus tests across the nation's health care system.

Effective for dates of service on or after March 1, 2020, the Centers for Medicare and Medicaid Services (CMS) has also established Healthcare Common Procedure Coding System (HCPCS) billing codes, G2023 and G2024 to identify and reimburse specimen collection for COVID-19 testing. These codes are billable and separately reimbursed for professional providers e.g. physicians and Advanced Practice Providers or by clinical diagnostic laboratories.

CODING

BlueCHiP for Medicare and Commercial Products

The following codes for diagnostic laboratory testing are to be billed by the laboratory processing the test and are covered with no cost share effective for the dates of service identified above:

87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique

U0001 CDC 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel

U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc

The following HCPCS codes for specimen collection are covered and separately reimbursed with no cost share effective for the dates of service identified above for professional providers e.g. physicians and Advanced Practice Providers, facilities such as hospitals for outpatient services, SNF's for non-skilled patients, home care agencies or by clinical diagnostic laboratories.

G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source

G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source.

REIMBURSEMENT

BCBSRI reserves the right to audit medical and/or any administrative records related to adherence to all the requirements of this policy.

RELATED POLICIES

Telemedicine/Telehealth and Telephone Services – **TEMPORARY** Policy - Effective 3/18/20

TEMPORARY COVID-19 Encounter for Determination of Need for COVID-19 Diagnostic Testing

TEMPORARY Timely Filing Limit Extension Policy – Additional 180 Days

PUBLISHED

BCBSRI's website under Medical and Payment Policies

REFERENCES

Not applicable

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

